Keybank National Association OH Boosts Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Keybank National Association OH lifted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 61.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,315 shares of the medical equipment provider's stock after purchasing an additional 5,434 shares during the quarter. Keybank National Association OH's holdings in Zimmer Biomet were worth $1,620,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Dorsey & Whitney Trust CO LLC raised its holdings in shares of Zimmer Biomet by 2.3% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider's stock worth $485,000 after buying an additional 102 shares during the period. M&T Bank Corp boosted its position in Zimmer Biomet by 0.4% during the 4th quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider's stock valued at $2,834,000 after acquiring an additional 108 shares in the last quarter. MGO One Seven LLC boosted its position in Zimmer Biomet by 5.1% during the 4th quarter. MGO One Seven LLC now owns 2,254 shares of the medical equipment provider's stock valued at $238,000 after acquiring an additional 110 shares in the last quarter. Janney Montgomery Scott LLC lifted its holdings in shares of Zimmer Biomet by 0.5% during the 1st quarter. Janney Montgomery Scott LLC now owns 25,647 shares of the medical equipment provider's stock valued at $2,903,000 after purchasing an additional 118 shares during the last quarter. Finally, FWG Holdings LLC lifted its holdings in shares of Zimmer Biomet by 3.5% during the 4th quarter. FWG Holdings LLC now owns 3,715 shares of the medical equipment provider's stock valued at $402,000 after purchasing an additional 124 shares during the last quarter. 88.89% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ZBH has been the subject of a number of research analyst reports. Morgan Stanley reduced their target price on Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Stifel Nicolaus set a $115.00 price objective on Zimmer Biomet and gave the company a "buy" rating in a research note on Tuesday, May 6th. Raymond James Financial dropped their target price on Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Royal Bank Of Canada dropped their target price on Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Finally, BTIG Research reiterated a "buy" rating on shares of Zimmer Biomet in a report on Monday, April 14th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $110.56.

Zimmer Biomet Trading Up 1.8%

ZBH traded up $1.69 during trading hours on Wednesday, reaching $95.16. The company's stock had a trading volume of 2,769,743 shares, compared to its average volume of 1,817,176. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $89.22 and a fifty-two week high of $116.71. The stock has a market cap of $18.83 billion, a PE ratio of 21.05, a P/E/G ratio of 2.16 and a beta of 0.71. The business's 50-day moving average is $93.51 and its 200-day moving average is $101.52. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.44 and a quick ratio of 1.46.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.73% and a net margin of 11.86%. The company had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. During the same quarter in the previous year, the company earned $1.94 earnings per share. The firm's quarterly revenue was up 1.1% compared to the same quarter last year. As a group, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.01%. The ex-dividend date of this dividend is Thursday, June 26th. Zimmer Biomet's dividend payout ratio (DPR) is 21.24%.

Insider Activity

In other news, insider Sang Yi sold 1,000 shares of the stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total value of $95,000.00. Following the sale, the insider directly owned 20,424 shares in the company, valued at approximately $1,940,280. This trade represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.39% of the company's stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.